Sarepta Therapeutics (NASDAQ:SRPT) stock price target increased to $108.00, reported today by RBC Capital Markets
- Updated: October 2, 2016
Sarepta Therapeutics (NASDAQ:SRPT) had its price target upped to $108.00 by RBC Capital Markets in an issued report announced 9/28/2016. The latest stock price target implies a possible upside of 0.83% based on the company's most recent stock price close.
On Tuesday September 20, 2016, SunTrust Banks Inc. reported on Sarepta Therapeutics (NASDAQ:SRPT) increased the target price from $4.00 to $48.00 that suggested a downside of -0.14%.
Displaying a price of $59.10, Sarepta Therapeutics (NASDAQ:SRPT) traded 0.71% higher on the day. The last stock close price is up 157.68% from the two hundred day average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same period. The company has recorded a 50-day moving average of $35.91 and a 200-day moving average of $23.83. Volume of trade was down over the average, with 2,507,794 shares of SRPT changing hands under the typical 4,077,750
See Chart Below
Sarepta Therapeutics has a one year low of $8.00 and a one year high of $63.73 Sarepta Therapeutics’s market capitalization is currently $0.
In addition to RBC Capital Markets reporting its stock price target, a total of 13 brokerages have issued a ratings update on the stock. The consensus target price is $20.77 with 3 firms rating the stock a strong buy, 1 firm rating the stock a buy, 5 brokers rating the stock a hold, 4 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.
General Information About Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.